Drug Profile
Research programme: Zika virus vaccine - GT Biopharma
Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator University of Pittsburgh
- Developer GT Biopharma; University of Pittsburgh
- Class Antivirals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in Zika-virus-infection in USA
- 28 Apr 2020 No recent reports of development identified for research development in Zika-virus-infection(Prevention) in USA
- 07 Aug 2017 Oxis International is now called GT Biopharma